FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118014730> ?p ?o ?g. }

• W2118014730 abstract "Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies and tends to be relatively resistant to conventional therapies. Activated Ras oncogene mutations are found in up to 90% of PDAC, leading to activation of the Ras/Raf/MEK/ERK signaling pathway. Sorafenib is a multikinase inhibitor of the Ras/Raf/MEK/ERK pathway and of tumor angiogenesis. Endothelial monocyte activating polypeptide II (EMAP) enhances gemcitabine effects in PDAC. Antitumor activity of sorafenib was evaluated in combination with gemcitabine (Gem) and the antiangiogenic agent EMAP in experimental PDAC. Methods Cell proliferation and protein expression were analyzed by WST-1 assay and Western blotting. Animal survival studies were performed in murine PDAC xenografts. Results Sorafenib decreased phospho-MEK, phospho-ERK1/2, phospho-p70S6K and phospho-4EBP-1 expression in PDAC cells. Sorafenib inhibited in vitro proliferation of all four PDAC cell lines tested. Additive effects on cell proliferation inhibition were observed in the gemcitabine-sorafenib combination in PDAC cells, and in combinations of sorafenib or EMAP with gemcitabine in endothelial (HUVEC) and fibroblast (WI-38) cells. Sorafenib, alone or in combination with gemcitabine and EMAP, induced apoptosis in HUVECs and WI-38 cells as observed via increased expression of cleaved poly (ADP-ribose) polymerase-1 (PARP-1) and caspase-3 proteins. Compared to controls (median survival: 22 days), animal survival increased after Gem therapy (29 days) but not in sorafenib (23 days) or EMAP therapy alone (25 days). Further increases in survival occurred in combination therapy groups Gem+sorafenib (30 days, p=0.004), Gem+EMAP (33 days, p=0.002), and Gem+sorafenib+EMAP (36 days, p=0.004), but not after the sorafenib+EMAP combination (24 days). Conclusions These findings demonstrate that the addition of a polymechanistic antiangiogenic agent such as EMAP can enhance the combination treatment effects of sorafenib and cytotoxic PDAC therapy." @default.
• W2118014730 created "2016-06-24" @default.
• W2118014730 creator A5002487860 @default.
• W2118014730 creator A5006708086 @default.
• W2118014730 creator A5047602817 @default.
• W2118014730 creator A5048386880 @default.
• W2118014730 creator A5055707568 @default.
• W2118014730 date "2013-03-06" @default.
• W2118014730 modified "2023-10-18" @default.
• W2118014730 title "Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II" @default.
• W2118014730 cites W1931508686 @default.
• W2118014730 cites W1965851372 @default.
• W2118014730 cites W1968146996 @default.
• W2118014730 cites W1979594711 @default.
• W2118014730 cites W1993415191 @default.
• W2118014730 cites W2005076892 @default.
• W2118014730 cites W2006131587 @default.
• W2118014730 cites W2020114724 @default.
• W2118014730 cites W2025970479 @default.
• W2118014730 cites W2029505291 @default.
• W2118014730 cites W2034336067 @default.
• W2118014730 cites W2047964609 @default.
• W2118014730 cites W2061345986 @default.
• W2118014730 cites W2061953474 @default.
• W2118014730 cites W2062809449 @default.
• W2118014730 cites W2068322424 @default.
• W2118014730 cites W2073341281 @default.
• W2118014730 cites W2074431706 @default.
• W2118014730 cites W2075863736 @default.
• W2118014730 cites W2078194579 @default.
• W2118014730 cites W2080557886 @default.
• W2118014730 cites W2082777374 @default.
• W2118014730 cites W2084555154 @default.
• W2118014730 cites W2084875329 @default.
• W2118014730 cites W2086462357 @default.
• W2118014730 cites W2086595248 @default.
• W2118014730 cites W2089225273 @default.
• W2118014730 cites W2097482835 @default.
• W2118014730 cites W2106787323 @default.
• W2118014730 cites W2118952669 @default.
• W2118014730 cites W2121308207 @default.
• W2118014730 cites W2121823666 @default.
• W2118014730 cites W2125131472 @default.
• W2118014730 cites W2128095147 @default.
• W2118014730 cites W2140765540 @default.
• W2118014730 cites W2151253787 @default.
• W2118014730 cites W2159441446 @default.
• W2118014730 cites W2161884651 @default.
• W2118014730 cites W2162651519 @default.
• W2118014730 cites W2326858971 @default.
• W2118014730 cites W96205076 @default.
• W2118014730 doi "https://doi.org/10.1186/1756-9966-32-12" @default.
• W2118014730 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3618297" @default.
• W2118014730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23497499" @default.
• W2118014730 hasPublicationYear "2013" @default.
• W2118014730 type Work @default.
• W2118014730 sameAs 2118014730 @default.
• W2118014730 citedByCount "22" @default.
• W2118014730 countsByYear W21180147302013 @default.
• W2118014730 countsByYear W21180147302014 @default.
• W2118014730 countsByYear W21180147302015 @default.
• W2118014730 countsByYear W21180147302016 @default.
• W2118014730 countsByYear W21180147302018 @default.
• W2118014730 countsByYear W21180147302019 @default.
• W2118014730 countsByYear W21180147302020 @default.
• W2118014730 countsByYear W21180147302021 @default.
• W2118014730 countsByYear W21180147302022 @default.
• W2118014730 countsByYear W21180147302023 @default.
• W2118014730 crossrefType "journal-article" @default.
• W2118014730 hasAuthorship W2118014730A5002487860 @default.
• W2118014730 hasAuthorship W2118014730A5006708086 @default.
• W2118014730 hasAuthorship W2118014730A5047602817 @default.
• W2118014730 hasAuthorship W2118014730A5048386880 @default.
• W2118014730 hasAuthorship W2118014730A5055707568 @default.
• W2118014730 hasBestOaLocation W21180147301 @default.
• W2118014730 hasConcept C121608353 @default.
• W2118014730 hasConcept C126322002 @default.
• W2118014730 hasConcept C185592680 @default.
• W2118014730 hasConcept C190283241 @default.
• W2118014730 hasConcept C2778019345 @default.
• W2118014730 hasConcept C2778695046 @default.
• W2118014730 hasConcept C2780210213 @default.
• W2118014730 hasConcept C2780258809 @default.
• W2118014730 hasConcept C2780394083 @default.
• W2118014730 hasConcept C2781018059 @default.
• W2118014730 hasConcept C29537977 @default.
• W2118014730 hasConcept C502942594 @default.
• W2118014730 hasConcept C55493867 @default.
• W2118014730 hasConcept C57074206 @default.
• W2118014730 hasConcept C62478195 @default.
• W2118014730 hasConcept C71924100 @default.
• W2118014730 hasConcept C98274493 @default.
• W2118014730 hasConceptScore W2118014730C121608353 @default.
• W2118014730 hasConceptScore W2118014730C126322002 @default.
• W2118014730 hasConceptScore W2118014730C185592680 @default.
• W2118014730 hasConceptScore W2118014730C190283241 @default.
• W2118014730 hasConceptScore W2118014730C2778019345 @default.
• W2118014730 hasConceptScore W2118014730C2778695046 @default.
• W2118014730 hasConceptScore W2118014730C2780210213 @default.
• W2118014730 hasConceptScore W2118014730C2780258809 @default.

• next